Cited by 794Sepsis Diagnosis and TreatmentInflammation biomarkers and pathwaysAntibiotics Pharmacokinetics and Efficacy

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Fisher, Charles J.·1994·JAMA

DOI 10.1001/jama.1994.03510470040032

Open this paper in CoChat — free account

Abstract

Objective. —To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. Study Design. —Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. Population. —A total of 893 patients with sepsis syndrome received an intravenous loading dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion of rhIL-1ra (1.0 or 2.0 mg/kg per hour) or placebo. Outcome Measure. —Twenty-eight—day all-cause mortality. Results. —There was not a significant increase in survival time for rhIL-1ra treatment compared with placebo among all patients who received the study medication (n=893; generalized Wilcoxon statistic,P=.22) or among patients with shock at study entry (n=713; generalized Wilcoxon statistic,P=.23), the two primary efficacy analyses specified a priori for this trial. Results from secondary analyses suggest an increase in survival time with rhIL-1ra treatment among patients with dysfunction of one or more organs (n=563; linear dose-response,P=.009). Retrospective analysis demonstrated an increase in survival time with rhIL-1ra treatment among patients with a predicted risk of mortality of 24% or greater (n=580; linear dose-response,P=.005) as well as among patients with both dysfunction of one or more organs and a predicted risk of mortality of 24% or greater (n=411; linear dose-response,P=.002). Conclusions. —There was not a statistically significant increase in survivial time for rhIL-1ra treatment compared with placebo among all patients who received the study medication or among patients with shock at study entry. Secondary and retrospective analyses of efficacy suggest that treatment with rhIL-1ra results in a dose-related increase in survival time among patients with sepsis who have organ dysfunction and/or a predicted risk of mortality of 24% or greater. (JAMA. 1994;271:1836-1843)

Integrity signals

Registry

Crossref · 10.1001/jama.1994.03510470040032

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The publisher hasn’t deposited this paper’s reference list.

Sorted by citations

Items 601–700 of 794

Leukocyte—Endothelial Cell Interactions: Review of Adhesion Molecules and Their Role in Organ Injury
Shrotri, M. S., Peyton, J. C., & Cheadle, W. G. (2000) · Springer eBooks · doi:10.1007/978-1-4612-1222-5_24 · Cited by 5
Physiological classification and stratification of illness severity of posttrauma 'sepsis' patients as a basis for randomization of clinical trials
Siegel, J. H., Rixen, D., & Friedman, H. P. (1995) · Journal of Endotoxin Research · doi:10.1177/096805199500200306 · Cited by 5
Predisposing factors: effect of sex, nutritional factors and age on immunity following shock and sepsis
Zellweger, R., Ayala, A., & Chaudry, I. H. (1999) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8755-7_4 · Cited by 5
Identification of host endotypes using peripheral blood transcriptomics in a prospective cohort of patients with endocarditis
Duarte-Herrera, I. D., López‐Martínez, C., Rodríguez-García, R., Parra, D., Martín-Vicente, P., Exojo-Ramírez, S. M., Miravete-Lagunes, K., Iglesias, L., González-Iglesias, M., Fernández-Rodríguez, M., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107235 · Cited by 4
Dimethyl fumarate attenuates liver injury in a mouse model of cecal ligation and puncture by modulating inflammatory, angiogenic and pyroptotic pathways
Qassam, H. S., Janabi, A. M., Gaen, K. K., & Hadi, N. R. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00968-2 · Cited by 4
Platelets in Neonatal Sepsis: Beyond Clotting, from Silent Players to Immune Orchestrators
Sokou, R., Lianou, A., Tsantes, A. G., Petrou, E., Bonovas, S., Nikolopoulos, G. K., Tsantes, A. Ε., & Iacovidou, N. M. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2731-2399 · Cited by 4
The Role of PI3k-Gamma Modulation in Bacterial Infection: A Review of the Literature and Selected Experimental Observations
Sun, D., Hoffman, A., Askarian, F., Bjånes, E., Lin, E. X., Varner, J. A., & Nizet, V. (2025) · Antibiotics · doi:10.3390/antibiotics14030315 · Cited by 4
“Existing therapies aimed at controlling inﬂammation, such as steroids and cytokine-targeting antibodies, have shown limited success and often risk impairing immune cell function to the extent that infection prevails [107–111].”
Therapeutic targeting of inflammasome signaling by blocking interleukin-1
Coll, R. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91802-2.00010-4 · Cited by 3
Macrophage Activation Syndrome
Iosim, S., & Henderson, L. A. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.02.004 · Cited by 5
Pro-inflammatory and Anti-inflammatory Mediators in Critical Illness and Injury
Muszynski, J. A., Frazier, W. J., & Hall, M. W. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6362-6_22 · Cited by 4
“It should also be understood that therapies targeting individual pro-infl ammatory cytokines have been attempted without success in multiple clinical trials in the setting of sepsis in adults [ 14 – 16 ].”
Background
Epidemiology, Risk Factors, and Outcome of Multiple Organ Dysfunction Syndrome in Surgical Patients
Barie, P. S., & Hydo, L. J. (2000) · Springer eBooks · doi:10.1007/978-1-4612-1222-5_6 · Cited by 5
Could treatment with immunomodulatory agents targeting IL-1, IL-6, or JAK signalling improve outcomes in patients with severe influenza pneumonia? A systematic and narrative review
Hays, L. M. C., Black, M., Prunty, M. P., Murthy, S., van de Veerdonk, F. L., Annane, D., Binnie, A., Burrell, A. J. C., Derde, L. P. G., Gordon, A. C., et al. (2022) · HRB Open Research · doi:10.12688/hrbopenres.13613.1 · Cited by 4
Protein-mediated interactions in the dynamic regulation of acute inflammation
Stark, R. J. (2023) · Biocell · doi:10.32604/biocell.2023.027838 · Cited by 4
Bacteria-Associated Cytokine Storm Syndrome
Eloseily, E. M., & Cron, R. Q. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-59815-9_19 · Cited by 4
Elastase Inhibitors in the Lung: Expression and Functional Relationships
Sallenave, J., Morgan, K., Gauldie, J., & Kalsheker, N. A. (1999) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8831-8_5 · Cited by 4
Initial levels of organ failure, microbial findings and mortality in intensive care-treated primary, secondary and tertiary sepsis
Castegren, M., Jonasson, M., Castegren, S., Lipcsey, M., & Sjölin, J. (2015) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01485-0 · Cited by 4
Clinically-oriented therapies in sepsis: a review
Dubois, M., & Vincent, J. (2000) · Journal of Endotoxin Research · doi:10.1177/09680519000060060901 · Cited by 4
Cytokine inhibitors for sepsis and septic shock
Orlicek, S. L. (2001) · Seminars in Pediatric Infectious Diseases · doi:10.1053/spid.2001.19232 · Cited by 4
Prophylactic uses of integrin CD18-βA peptide in a murine polymicrobial peritonitis model
Wong, K. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i21.2648 · Cited by 4
The Systemic Mediator-Associated Response Test Identifies Patients in Failed Sepsis Clinical Trials Among Whom Novel Drugs Reduce Mortality
Slotman, G. J. (2011) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3182159c61 · Cited by 4
Comparison of Specific Adsorbents for Tumor Necrosis Factor-α and Therapeutic Anti-Tumor Necrosis Factor-α Antibodies: An in Vitro Sepsis Model
Schwanzer-Pfeiffer, D., Mitteregger, R., Roßmanith, E., & Falkenhagen, D. (2006) · The International Journal of Artificial Organs · doi:10.1177/039139880602901207 · Cited by 4
Effects of bactericidal/permeability-increasing protein on endotoxin-induced fever and Escherichia coli-induced shock in rabbits
Porat, R., Paddock, H. N., Cominelli, F., et al. (1995) · Journal of Endotoxin Research · doi:10.1177/096805199500200102 · Cited by 4
Evaluating the autoinduction expression system and one‐step purification for high‐level expression and purification of gallbladder‐derived rhIL‐1Ra
Bashir, H., Ahmed, N., Khan, M. A., Zafar, A. U., Tahir, S., Kanwal, H., Khan, F., Rahman, Z. U., & Husnaın, T. (2015) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1463 · Cited by 3
Sepsis
Shanley, T. P., Hallstrom, C., & Wong, H. R. (2006) · Elsevier eBooks · doi:10.1016/b978-032301808-1.50099-7 · Cited by 3
Inflammatory Mediators in Neonatal Asphyxia and Infection
Okazaki, K., Nishida, A., & Kimura, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-18159-2_248-1 · Cited by 4
Progress on the application of growth factor-related drugs in ophthalmology
Xiaojie, W. A. N. G., Qi, H. U. I., Jin, Z. Y., et al. (2022) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2022-0075 · Cited by 3
Fibronectin extra domain a limits liver dysfunction and protects mice during acute inflammation
Venu, V. K. P., Moregola, A., Dalt, L. D., Uboldi, P., Bonacina, F., Muro, A. F., & Norata, G. D. (2023) · Atherosclerosis Plus · doi:10.1016/j.athplu.2023.05.002 · Cited by 3
Amino acid and dipeptide combination strongly attenuates endotoxemic cytokine production in human whole-blood monocytes
Raspé, C., Czeslick, Leimert, Rossberg, Hofmann, Simm, Weimann, & Sablotzki (2013) · International Journal of Interferon Cytokine and Mediator Research · doi:10.2147/ijicmr.s41683 · Cited by 3
International comparisons of intensive care: Meeting the challenges of different worlds of intensive care
Mata, G. V., Rowan, K., Zimmerman, J. E., et al. (1996) · Intensive Care Medicine · doi:10.1007/bf01720722 · Cited by 3
Rationale for the Use of Intravenous Immunoglobulin in Streptococcal Necrotising Fasciitis
Yong, J. (1995) · BioDrugs · doi:10.1007/bf03259071 · Cited by 3
Effects of anti-interleukin 6 on inflammatory responses during murine septic peritonitis
van der Poll, T., Keogh, C. V., HELFGOTT, D. C., Berman, L., Buurman, W. A., & Lowry, S. F. (1996) · Journal of Endotoxin Research · doi:10.1177/096805199600300604 · Cited by 3
Inflammatory Diseases and the Heart
Sherman, B., & Haspel, K. L. (2012) · International Anesthesiology Clinics · doi:10.1097/aia.0b013e3182516ee8 · Cited by 3
“Infusions of the recombinant IL-1 receptor antagonist were attempted but did not lead to a significant survival benefit.(38) IL-6 is another proinflammatory cytokine that is suspected in the pathogenesis of sepsis and has a prolonged elevation in the circulation.”
Background
High Efficiency Removal of Cytokines and HMGB‐1 by Continuous Hemofiltration With a Dual Layered Polyethersulfone Membrane: An Ex Vivo Study
Ohchi, Y., Goto, K., Yasuda, N., et al. (2018) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12767 · Cited by 3
The Systemic Inflammatory Response Syndrome (SIRS), Sepsis, and Septic Shock
Guzman‐Cottrill, J. A., Cheesebrough, B., Nadel, S., & Goldstein, B. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2702-9.00011-8 · Cited by 3
The systemic inflammatory response syndrome
Sherwood, E. R., & Traber, D. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2786-9.00021-7 · Cited by 3
Research in the Intensive Care Unit
Marshall, J. C., Cook, D. J., & Hébert, P. C. (1998) · Springer eBooks · doi:10.1007/978-1-4612-1888-3_52 · Cited by 3
Influence of cytokines on the renal circulation and nephron function
Schelling, J. R., & Sedor, J. R. (1998) · Springer eBooks · doi:10.1007/978-94-011-5482-6_41 · Cited by 3
Pathophysiologie, Klinik und Therapie intensivmedizinischer Krankheitsbilder mit DIC
Bohrer, H., & Nawroth, P. P. (1996) · Springer eBooks · doi:10.1007/978-3-662-12220-4_1 · Cited by 3
Quelles perspectives thérapeutiques dans le syndrome septique ?
Léone, M., Bourgoin, A., Antonini, F., Albanèse, J., & Martin, C. M. P. (2003) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2003.08.003 · Cited by 3
Shifting Ground: Enteral vs Parenteral Nutrition in Critically Ill Patients
Dahn, M. S. (1994) · Nutrition in Clinical Practice · doi:10.1177/0115426594009005163 · Cited by 3
Blocking interleukin-1 in sepsis
Dinarello, C. A. (1995) · Journal of Endotoxin Research · doi:10.1177/096805199500200303 · Cited by 3
Recent Advances: Antiinfectives
Briceland, L. L., Cleary, J. D., Fletcher, C. V., et al. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502901015 · Cited by 3
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study‘
Calvo-Aranda, E., Orbis, I. C., Novella-Navarro, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219479 · Cited by 3
Treating and triggering hyperinflammation: tackling hemophagocytic lymphohistiocytosis and HLH-like syndromes in the pediatric cell therapy and critical care setting
Wobma, H., Henderson, L. A., Duncan, C., Prockop, S. E., Randolph, A. G., Degar, B. A., Lehmann, L., & Baumeister, S. H. C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1631557 · Cited by 3
Hyper-inflammation and immunosuppression: redefining sepsis therapy using modern approaches
Prajapati, M., Singh, V., Mishra, A., Khatua, D., Rana, M., & Jyoti, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1810887 · Cited by 2
“Secondary analyses suggested only a possible dose–response benefit in certain high-risk subgroups (e.g., organ dysfunction, high baseline mortality risk) (Fisher et al., 1994).”
Immunomodulation in critically ill septic patients
Azkol, M., Helal, S., Hassan, G., et al. (2015) · Menoufia Medical Journal · doi:10.4103/1110-2098.156005 · Cited by 2
Sepsis
Clarke, G. M. (2001) · Springer eBooks · doi:10.1007/978-1-4757-6645-5_25 · Cited by 2
Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis
Vastert, S. J., Canny, S., Canna, S., Schneider, R., & Mellins, E. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-59815-9_23 · Cited by 2
The Treatment of Sepsis: From Failed Therapies to New Possibilities
Chung, H., Rochwerg, B. N., & Fox‐Robichaud, A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801078-5.00017-0 · Cited by 2
Interleukin-1 Receptor Antagonist Treatment in Rheumatoid Arthritis
Bresnihan, B. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-239-5_7 · Cited by 2
Metabolic Depletion and Failure: Muscle Cachexia During Injury and Sepsis
Pritts, T. A., Fischer, D. R., & Hasselgren, P.-O. (2000) · Springer eBooks · doi:10.1007/978-1-4612-1222-5_38 · Cited by 2
Applying lessons learned from anti-endotoxin therapy
Scannon, P. J. (1995) · Journal of Endotoxin Research · doi:10.1177/096805199500200312 · Cited by 2
Inflammatory Mediators in Neonatal Asphyxia and Infection
Okazaki, K., Nishida, A., & Kimura, H. (2018) · Springer eBooks · doi:10.1007/978-3-319-29489-6_248 · Cited by 2
“Although anti-inflammatory therapies are thought to be effective in humans, clinical trials have failed and adverse effects have been reported in some cases (Fisher et al. 1994, 1996).”
Background
Interleukin-1 Receptor Antagonist and Interleukin-1β: Risk Marker or Risk Factor for Pediatric Acute Respiratory Distress Syndrome?*
Ducharme‐Crevier, L., & Lacroix, J. (2018) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001713 · Cited by 2
Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis
Schneider, R., Canny, S., & Mellins, E. (2019) · Springer eBooks · doi:10.1007/978-3-030-22094-5_21 · Cited by 2
The Immune System in Critical Illness and Injury
Moreland, J. G. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6416-6_28 · Cited by 2
The Systemic Inflammatory Response Syndrome (SIRS), Sepsis, and Septic Shock
Guzman‐Cottrill, J. A., Nadel, S., & Goldstein, B. (2008) · Elsevier eBooks · doi:10.1016/b978-0-7020-3468-8.50018-3 · Cited by 2
Opioids, febrile responsiveness, and thinking outside the box
Ault, M. L. (2000) · Critical Care Medicine · doi:10.1097/00003246-200005000-00070 · Cited by 2
“targeted attacks on specific cytokines such as IL-1 (9) and TNF (10).”
Background
Sepsis Management: Importance of the Pathogen
McCulloh, R. J., & Opal, S. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-73506-1_11 · Cited by 2
Evidence-Based Surgery
McLeod, R. S. (2001) · Springer eBooks · doi:10.1007/978-3-642-57282-1_3 · Cited by 2
Cytokines, Heart and Calcium Current in Sepsis
Štengl, M., Průcha, M., & Matějovič, M. (2011) · Springer eBooks · doi:10.1007/978-94-007-2004-6_4 · Cited by 2
Chapter 4. Emerging Opportunities in Neuroinflammatory Mechanisms of Neurodegeneration
Shiosaki, K., & Puttfarcken, P. S. (1995) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60917-3 · Cited by 2
Medical Applications of Recombinant Proteins in Humans and Animals
Wetzel, G. D. (2001) · Biotechnology Set · doi:10.1002/9783527620999.ch5d · Cited by 2
Pathophysiology and Therapy of End-Organ Failure in Critical Illness
Pinsky, M. R. (1996) · Springer eBooks · doi:10.1007/978-88-470-2203-4_8 · Cited by 2
Risk Prediction and Outcome Description in Critical Surgical Illness
Marshall, J. C. (2001) · Springer eBooks · doi:10.1007/978-3-642-57282-1_18 · Cited by 2
Risk assessment in recent clinical trials in sepsis/SIRS: lessons learned and future directions
Knaus, W. A., Wagner, D. P., Sun, X., et al. (1995) · Journal of Endotoxin Research · doi:10.1177/096805199500200305 · Cited by 2
Novel Insights Into the Pathogenesis and Therapy of Circulatory Shock
Steingrub, J. S. (1998) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/108925329800200103 · Cited by 2
Future Directions in the Treatment of SIRS and MODS
Fry, D. E. (2000) · Springer eBooks · doi:10.1007/978-1-4612-1222-5_72 · Cited by 2
Interleukin-1 receptor antagonist
Smith, M. F. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8450-1_9 · Cited by 2
Diagnosis and Treatment of Infection
Dunn, D. L. (2001) · Springer eBooks · doi:10.1007/978-3-642-57282-1_11 · Cited by 2
Nitric Oxide and the Heart in Sepsis
Kumar, A., & Parrillo, J. E. (1995) · Update in intensive care and emergency medicine · doi:10.1007/978-3-642-79920-4_6 · Cited by 2
Clinical Outcome End Points and Assessment of Mechanical Ventilation Innovations
Dellinger, R. P. (1995) · Respiratory Care · doi:10.1177/194336549504000912 · Cited by 2
Endotoxin retention in adipose tissue leading to persistent hypotension in catecholamine-dependent acute obstructive suppurative cholangitis
Li, K., Zhu, S., Ye, C. J., Ding, Y., Liu, J., Wang, Y., Wang, Z., Li, W., Yang, D., Wang, X., et al. (2025) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2025-0053 · Cited by 1
Year in Review 2025: New and Noteworthy Literature in Cardiothoracic Critical Care
Alber, S. M., Kim, K. K., Li, X. R., Tanabe, K. J., & Gilliland, S. (2026) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/10892532261438445 · Cited by 1
Survival Analysis in the Regulatory Setting
Ellenberg, S. S., & Siegel, J. P. (1997) · Lecture notes in statistics · doi:10.1007/978-1-4684-6316-3_12 · Cited by 1
Sepsa w 2014 roku – kontrowersje i nowości
Buda, P., Migdał, M., Grenda, R., & Książyk, J. (2014) · Pediatria Polska · doi:10.1016/j.pepo.2014.12.002 · Cited by 1
Novel Inflammatory and Immunomodulatory Mediators in Sepsis
Cen, C., Aziz, M., & Wang, P. (2016) · Springer eBooks · doi:10.1007/978-981-10-2425-2_14 · Cited by 1
“Blockade of another pro-inflammatory cytokine, interleukin (IL)-1 using a receptor antagonist also failed to demonstrate a significant reduction in mortality compared with standard therapy [21, 22].”
Background
A new horizon for sepsis: Personalised medicine: Hype or hope?
McGalliard, R. J., & Carrol, E. D. (2017) · European Journal of Molecular & Clinical Medicine · doi:10.1016/j.nhtm.2017.06.002 · Cited by 1
Systemic Inflammatory Response Syndrome (SIRS) as an Insult-Induced Immune Dissonance: A Role for Lactoferrin
Kruzel, M. L., Kruzel, M. C., & Actor, J. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813832-8.00005-4 · Cited by 1
Interleukin (IL)-1 Blocking Compounds and Their Use in Autoinflammatory Diseases
Kallinich, T., & Benedetti, F. D. (2019) · Springer eBooks · doi:10.1007/978-3-319-98605-0_41 · Cited by 1
Targeting TLR-4 Signaling to Treat COVID-19-induced Acute Kidney Injury
Almazmomi, M. A., & Alsieni, M. (2022) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x221147798 · Cited by 1
Intravenous anakinra for treating macrophage activation syndrome in adult onset still’s disease
Bıtık, B., Şentürk, M., Kibaroğlu, S., et al. (2024) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2024_004788 · Cited by 1
Inflammatory Heart Disease in Multisystem Inflammatory Syndrome
Vecchia, G. L., Buono, M. G. D., Bonaventura, A., Vecchié, A., Moroni, F., Sanna, T., & Abbate, A. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02173-9 · Cited by 3
IL-1 receptor antagonist in the treatment of dry eye disease
Amparo, F., & Dana, R. (2013) · Expert Review of Ophthalmology · doi:10.1586/17469899.2013.851004 · Cited by 1
Systemic Inflammatory Response Syndrome
Lohmann, K. L., & Barton, M. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0891-8.00011-7 · Cited by 1
Acetylsalicylic acid of Eichengrin-Hoffmann, inflammatory mediators and issues of therapy of the initial stage of coronavirus infection COVID-19
Gumanova, N. G. (2020) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20202308183 · Cited by 1
Beyond Acute Traumatic Brain Injury: Molecular Implications of Associated Neuroinflammation in Higher-Order Cognitive Processes
Montivero, A., Ghersi, M., Catalan, J., Formica, M. L., Camacho, N., Culasso, A. F., Hereñú, C. B., Palma, S. D., & Pérez, M. F. (2021) · Springer eBooks · doi:10.1007/978-3-030-61721-9_20 · Cited by 1
NORMAL AND IMPAIRED IMMUNOLOGIC RESPONSES TO INFECTION
Tosi, M. F. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50007-8 · Cited by 2
Sepsis and Clinical Trials: a New Era in Anti-Sepsis Therapies
Vincent, J. (2002) · Springer eBooks · doi:10.1007/978-88-470-2213-3_16 · Cited by 1
Mediator-Directed Therapy in Pancreatitis and Trauma
Nathens, A. B. (1999) · Sepsis · doi:10.1023/a:1009826709338 · Cited by 1
Severity of disease in critically ill patients: Inflammatory parameters and clinical condition
Froon, A. H. M. (1999) · doi:10.26481/dis.19990910af · Cited by 1
Ulinastatin and thymosin as immune modulators for the treatment of sepsis
Luo, P. F., Ren, Y. T., Liu, Y., et al. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009940 · Cited by 1
Sepsis and Organ Dysfunction. The Challenge Continues
Berlot, G., Lucangelo, U., & Gullo, A. (2000) · Springer eBooks · doi:10.1007/978-88-470-2284-3_2 · Cited by 1
Clinical Trials for the Evaluation of Sepsis Therapies
Foster, D., & Doig, G. S. (1997) · Yearbook of intensive care and emergency medicine · doi:10.1007/978-3-662-13450-4_15 · Cited by 1
Carboxyhemoglobin in pediatric sepsis and the systemic inflammatory response syndrome
Shahin, A., Tamburro, R. F., & Schmidt, J. E. (2000) · Clinical Intensive Care · doi:10.3109/tcic.11.6.311.317 · Cited by 1
Adjunctive therapies for sepsis and septic shock
Breen, G., & Tunkel, A. R. (1999) · Current Infectious Disease Reports · doi:10.1007/s11908-999-0023-5 · Cited by 1
New advances in the pharmacologic approach to circulatory shock
Chernow, B. (1996) · Journal of Clinical Anesthesia · doi:10.1016/s0952-8180(96)90015-x · Cited by 1
Traitements immunomodulateurs du sepsis : l'état actuel des études cliniques
Baumgartner, J. D. (1996) · Réanimation Urgences · doi:10.1016/s1164-6756(05)80605-x · Cited by 1
Emerging Evidence of a More Complex Role for Proinflammatory and Antiinflammatory Cytokines in the Sepsis Response
Moldawer, L. L., Minter, R. M., & Rectenwald, J. E. (2000) · Springer eBooks · doi:10.1007/978-1-4612-1222-5_16 · Cited by 1
Anti-Inflammatory Therapy in Sepsis
Sevransky, J., & Natanson, C. (2001) · Perspectives on critical care infectious diseases · doi:10.1007/978-1-4615-1581-4_9 · Cited by 1

Authors: Fisher, C. J.
Corresponding author: Fisher, Charles J.
ORCID: Fisher, Charles J.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 1994-06-15
Volume: 271
Issue: 23
Pages: 1836
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.1994.03510470040032
OpenAlex: W4322697531
Cited by: 790
References: 0
Citations by year: 2026: 11 · 2025: 23 · 2024: 18 · 2023: 28 · 2022: 15 · 2021: 18 · 2020: 32 · 2019: 23 · 2018: 24 · 2017: 22 · 2016: 19 · 2015: 18 · 2014: 30 · 2013: 20 · 2012: 22
FWCI: 37.99
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Keywords: sepsis, septic shock, survival, organ dysfunction, mortality risk, dose-response relationship, drug safety, cytokine inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks